These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 29860282)

  • 61. Cognitive Decline in Alzheimer's Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting.
    Euesden J; Gowrisankar S; Qu AX; Jean PS; Hughes AR; Pulford DJ
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32370229
    [No Abstract]   [Full Text] [Related]  

  • 62. Development and validation of an interpretable deep learning framework for Alzheimer's disease classification.
    Qiu S; Joshi PS; Miller MI; Xue C; Zhou X; Karjadi C; Chang GH; Joshi AS; Dwyer B; Zhu S; Kaku M; Zhou Y; Alderazi YJ; Swaminathan A; Kedar S; Saint-Hilaire MH; Auerbach SH; Yuan J; Sartor EA; Au R; Kolachalama VB
    Brain; 2020 Jun; 143(6):1920-1933. PubMed ID: 32357201
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.
    Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW;
    Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 66. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.
    Cruchaga C; Kauwe JS; Mayo K; Spiegel N; Bertelsen S; Nowotny P; Shah AR; Abraham R; Hollingworth P; Harold D; Owen MM; Williams J; Lovestone S; Peskind ER; Li G; Leverenz JB; Galasko D; ; Morris JC; Fagan AM; Holtzman DM; Goate AM
    PLoS Genet; 2010 Sep; 6(9):e1001101. PubMed ID: 20862329
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia.
    Kim HJ; Lee JH; Cheong EN; Chung SE; Jo S; Shim WH; Hong YJ
    Curr Alzheimer Res; 2020; 17(10):893-903. PubMed ID: 33256581
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Genetic variation of oxidative phosphorylation genes in stroke and Alzheimer's disease.
    Biffi A; Sabuncu MR; Desikan RS; Schmansky N; Salat DH; Rosand J; Anderson CD;
    Neurobiol Aging; 2014 Aug; 35(8):1956.e1-8. PubMed ID: 24650791
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.
    Homann J; Osburg T; Ohlei O; Dobricic V; Deecke L; Bos I; Vandenberghe R; Gabel S; Scheltens P; Teunissen CE; Engelborghs S; Frisoni G; Blin O; Richardson JC; Bordet R; Lleó A; Alcolea D; Popp J; Clark C; Peyratout G; Martinez-Lage P; Tainta M; Dobson RJB; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Wittig M; Franke A; Lill CM; Blennow K; Zetterberg H; Lovestone S; Streffer J; Ten Kate M; Vos SJB; Barkhof F; Visser PJ; Bertram L
    Front Aging Neurosci; 2022; 14():840651. PubMed ID: 35386118
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of CR1 Genetic Variants on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts.
    Zhu XC; Wang HF; Jiang T; Lu H; Tan MS; Tan CC; Tan L; Tan L; Yu JT;
    Mol Neurobiol; 2017 Jan; 54(1):551-562. PubMed ID: 26742530
    [TBL] [Abstract][Full Text] [Related]  

  • 74. White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.
    Lindemer ER; Salat DH; Smith EE; Nguyen K; Fischl B; Greve DN;
    Neurobiol Aging; 2015 Sep; 36(9):2447-57. PubMed ID: 26095760
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Validating the role of the Australian National University Alzheimer's Disease Risk Index (ANU-ADRI) and a genetic risk score in progression to cognitive impairment in a population-based cohort of older adults followed for 12 years.
    Andrews SJ; Eramudugolla R; Velez JI; Cherbuin N; Easteal S; Anstey KJ
    Alzheimers Res Ther; 2017 Mar; 9(1):16. PubMed ID: 28259165
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genome-Wide Association Study of Brain Connectivity Changes for Alzheimer's Disease.
    Elsheikh SSM; Chimusa ER; Mulder NJ; Crimi A
    Sci Rep; 2020 Jan; 10(1):1433. PubMed ID: 31996736
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S; Passamonti L; Duggento A; Liò P; Toschi N;
    Neuroimage; 2019 Apr; 189():276-287. PubMed ID: 30654174
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
    Sintini I; Graff-Radford J; Senjem ML; Schwarz CG; Machulda MM; Martin PR; Jones DT; Boeve BF; Knopman DS; Kantarci K; Petersen RC; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    Brain; 2020 Jul; 143(7):2281-2294. PubMed ID: 32572464
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hippocampal Sclerosis of Aging, a Common Alzheimer's Disease 'Mimic': Risk Genotypes are Associated with Brain Atrophy Outside the Temporal Lobe.
    Nho K; Saykin AJ; ; Nelson PT
    J Alzheimers Dis; 2016; 52(1):373-83. PubMed ID: 27003218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.